0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.

Abstract

The atrophogenic potential of medium-potent topical glucocorticoids is still controversial. In a double-blind controlled trial 24 healthy volunteers either applied 0.25% prednicarbate cream or the corresponding vehicle to one and 0.1% betamethasone-17-valerate cream or 0.05% clobetasol-17-propionate cream to the other forearm twice daily. Skin thickness was regularly assessed during the six week period of application and for further three weeks thereafter, using both the B- and A-mode of a 20 MHz ultrasound scanner. Both betamethasone-17-valerate and clobetasol-17-propionate cream significantly reduced skin thickness as compared to cream base while prednicarbate cream did not. Given that 0.1% betamethasone-17-valerate- and 0.25% prednicarbate cream are reported to be about equipotent in the treatment of atopic eczema the latter preparation shows an increased ratio between its desired anti-inflammatory and its unwanted atrophogenic effect.

• Authors: H C Korting, D Vieluf, M Kerscher
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 42 Issue 2 Pg. 159-61 ( 1992) ISSN: 0031-6970 [Print] Germany
• PMID: 1618247 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Ointments
• Pharmaceutical Vehicles
• Betamethasone Valerate
• Prednisolone
• Clobetasol
• prednicarbate

Topics

• Adult
• Anti-Inflammatory Agents (adverse effects)
• Atrophy (chemically induced)
• Betamethasone Valerate (adverse effects)
• Clobetasol (adverse effects, analogs & derivatives)
• Double-Blind Method
• Female
• Humans
• Male
• Ointments
• Pharmaceutical Vehicles
• Prednisolone (adverse effects, analogs & derivatives)
• Skin (drug effects, pathology)